ERBB2 and breast carcinoma: In the subpopulation analysis of the registHER study, the median survival time after the first diagnosis of BM for total HER2-positive breast cancers was 13.0 months, and for patients diagnosed with BM subsequent to MBC diagnosis, it was 9.6 months (11).